Effects of tendamistate on postprandial plasma glucose, free fatty acid and triglyceride levels.

A dose of 400 mg tendamistate or a placebo was given to 10 volunteers in order to investigate its effects on plasma glucose, free fatty acid and triglyceride levels after a porridge meal. Each subject participated in two phases, in each of which they ate porridge prepared from 100 g maize meal together with either placebo or tendamistate 400 mg. Serial blood specimens for plasma glucose determinations were taken up to 3 hours after the meal, and those for free fatty acid and triglyceride determinations up to 14 hours after the meal.

Effects of tendamistate (an alpha-amylase inactivator), guar and placebo on starch metabolism.

Nine volunteers participated in a double-blind, cross-over study to compare the effects of tendamistate (HOE 467), guar and placebo on starch metabolism. In each phase of the trial they received a maize-meal porridge breakfast. They either received 5 g guar granules before the porridge or 100 mg tendamistate mixed with the porridge, or porridge alone.

Inhibition of starch absorption by tendamistate (an alpha-amylase inactivator).

Tendamistate (HOE 467) is an alpha-amylase inactivator. Doses of 100 and 200 mg and a placebo were administered to 6 volunteers in order to investigate the effect of the drug on plasma glucose levels after a bread meal. Each subject participated in three phases, in each of which they received a meal consisting of 200 g white bread together with either placebo or tendamistate 100 or 200 mg.

Effects of tendamistate (alpha-amylase inactivator) on starch metabolism.

Tendamistate (Hoe 467) reduces gastrointestinal absorption of starch by inactivating α-amylase. Two trials were performed to investigate the influence of timing and mode of administration of tendamistate, relative to starch intake, on the pharmacodynamics of the drug. (i) In the first trial 400 mg enteric coated capsules, 400 mg non-enteric coated capsules and placebo were compared in 12 volunteers.

The use of the SI in reporting results in chemical pathology--our experience.

Since 1 April 1974 some units of the SI have been introduced in the reporting of results from this laboratory. A change from the conventional way of expressing results to the new system requires careful planning and reorganisation. Our laboratory is the first in this country to make the change and our approach and experiences up to the present, are recorded.